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Core biopsy (CB) has now largely replaced fine-needle aspiration cytology (FNAC) in the preoperative assessment of breast cancer
in the UK. We studied the contribution of FNAC and CB in the preoperative diagnosis of screen-detected breast carcinoma. Data
were prospectively collected on 150840 women who underwent breast screening over a 4-year period from 1999 to 2003. Data on
women who had both FNAC and CB taken from the same lesion preoperatively and in whom surgical excision of the lesion
subsequently confirmed malignancy was analysed. In 763 cancers, FNAC was inadequate (C1) in 8% and benign (C2) in 10%. Most of
these cases presented with microcalcification (25% were C1 or C2). Core biopsy was not representative (B1) or benign (B2) in 7%.
The absolute and complete sensitivities were 65 and 82% for FNAC and 80 and 93% for CB in the diagnosis of cancer. Core biopsy
was abnormal (B3 or above) in 86% of the cancers missed by FNAC and FNAC was abnormal (C3 or above) in 65% of those missed
by CB. Core biopsy is better than FNAC at preoperative diagnosis of screen-detected breast cancer as it missed fewer cancers.
However, combining FNAC resulted in a better preoperative diagnosis rate.
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The National Health Service Breast Screening Programme
(NHSBSP) was introduced in the United Kingdom in 1987,
following publication of the findings of an expert committee the
previous year. At present, all women aged 50–70 years are offered
two-view screening mammography every 3 years. Patients with
radiologically suspicious lesions are recalled for further assessment
that may include clinical examination, special mammographic
views, ultrasound and collection of tissue for pathological
assessment by fine-needle aspiration cytology (FNAC), core biopsy
(CB), or more recently, by wide bore vacuum biopsy.
In the early stages of NHSBSP, FNAC was the test used in the
assessment. Core biopsy was introduced in the assessment process
in late 1990s. The experience with this technique has improved
considerably and CB is now considered to be the standard. The
preoperative diagnosis rate of screen-detected carcinoma has been
improving with increasing use of CB. Correspondingly, the use of
FNAC is in decline and a number of screening units in the UK have
abandoned it completely (Britton et al, 1997).
At the Bedfordshire and Hertfordshire Breast Screening Unit, CB
was introduced in the assessment of screen-detected breast lesions
in 1997, but we continued to perform FNAC in addition in the
majority of patients with suspicious lesions. The aim of this study
was to assess the performance of FNAC and CB in the preoperative
diagnosis of screen-detected breast carcinoma.
MATERIALS AND METHODS
Data were prospectively collected on all women who attended the
Bedfordshire and Hertfordshire Breast Screening Unit, England.
We reviewed a 4-year period from April 1999 to March 2003. This
period was chosen to ensure that operators had gained sufficient
expertise in the use of CB, which was introduced in 1997. We
selected, for detailed analysis, the women who had both FNAC and
CB performed at the preoperative diagnostic assessment and
had malignancy confirmed by subsequent surgery. In patients
who have had more than one assessment (if they were recalled
for further biopsies, etc), only the initial assessment was
considered.
Fine-needle aspiration cytology and CB were performed under
image guidance (either ultrasound or stereotaxis), or clinically by a
breast radiologist or breast physician. Fine-needle aspiration
cytology was performed first using a 21G needle attached to a
10ml syringe, and CB was performed using an automated device
(14G). When FNAC was performed under stereotaxis, five needle
passes were routinely undertaken, and under ultrasound or clinical
guidance 1–2 passes were performed. When CB was guided by
stereotaxis, five passes were routinely undertaken, and the
specimens were checked for calcification by radiography if
appropriate. If no calcification was obtained as many passes as
reasonably possible were made until calcium was retrieved. Two
to three passes were undertaken when CB was clinically or
sonographically guided. Local anaesthetic (LA) was not used for
FNAC, except when FNAC was performed under stereotaxis, where
multiple passes were undertaken. When LA was used, FNAC was
performed using a different needle to that which was used to
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sadminister the LA. Local anaesthetic was always used for CB.
Immediate evaluation of the FNAC was not performed routinely.
The outcomes of FNAC and CB were reported using the standard
NHSBSP criteria (Table 1). Sensitivity of FNAC and CB were
calculated in two ways (Britton, 1999): absolute sensitivity
included only C5 or B5 results and complete sensitivity included
C3, C4 and C5 for FNAC and B3, B4 and B5 for CB. We were unable
to calculate the specificity of tests, as radiologically nonsuspicious
lesions producing benign FNAC and CB are not surgically excised
in our practice. The miss rate for CB was defined as the proportion
of all breast cancers (invasive and ductal carcinoma in situ (DCIS))
with a diagnosis of only benign findings (B1 or B2) on CB.
RESULTS
During the study period, 150840 women underwent breast
screening and 5285 were recalled for further assessment of a
screen-detected lesion in the breast, an overall recall rate of 3.5%.
Among these, 2092 had both FNAC and CB performed and 869 of
these patients proceeded to surgery where histology confirmed
malignancy (DCIS or invasive) in 763 cases. Another 902 patients
had either FNA (n¼803) or CB (n¼99) but not both, and 72
patients in this group were also diagnosed with cancer (total
number of cancers 835), which gives an overall cancer detection
rate of 5.53/1000 in this group. Those 763 patients who had both
FNAC and CB, in whom malignancy was subsequently confirmed
by surgery, constitute the study population. Six hundred and
twenty-five patients had breast-conserving surgery and 138 had
mastectomy.
The final histology consists of invasive ductal carcinoma (IDC)
(n¼408, 53%), invasive lobular carcinoma (ILC) (n¼93, 12%),
mixed ductal and lobular carcinoma (n¼33, 4%) or tubular
carcinoma (TC) (n¼32, 4%) with or without DCIS. One hundred
and seventy-six patients (23%) had DCIS only. The remaining 21
patients had invasive carcinomas of other types.
Mammographic presentation
The mammographic lesions were classified as microcalcification in
231 cases and a soft tissue lesion (mass, mass associated with
microcalcification, asymmetrical density or stromal deformity) in
532 cases.
Mode (clinical, stereotactic or US) by which FNAC and CB
were performed
The data on the mode by which FNAC and CB were performed are
presented in Table 2. In 73% of patients (n¼555), both tests were
performed using the same mode. Relatively more FNACs were
performed clinically without image guidance compared with CB
(n¼208 and 86, respectively).
Outcome of FNAC and CB (Table 3)
Absolute sensitivity, which considers only the definitely malignant
(C5 or B5) results, was 80% for CB and 65% for FNAC. Complete
sensitivity, which considers all abnormal results (B3 and above and
C3 and above), was 93 and 82%, respectively. When both tests are
combined, the absolute sensitivity was 87% and complete
sensitivity was 98%. Complete sensitivity of FNAC varied with
the final histology: it was 89% for IDC, 73% for ILC, 81% for mixed
ductal and lobular carcinoma, 72% for TC and 73% for DCIS.
Corresponding figures for CB were 92, 98, 94, 86 and 94%,
respectively. Overall, the complete sensitivity of CB was higher
than that of FNAC regardless of whether the tumour was DCIS or
invasive, mammographic presentation (microcalcification or soft
tissue lesion) or the mode (clinical, US or stereotaxis) of biopsy
(Table 4). Core biopsy suggested (B3 or above) 86% of the cancers
missed by FNAC and FNAC was abnormal (C3 or above) in 65%
of those missed by CB. When only the 555 patients who had
both tests performed under the same modality (clinical, US or
stereotaxis) were considered, the absolute and complete sensiti-
vities were 62 and 78% for FNAC and 80 and 93% for CB,
respectively. The corresponding figures for the combination were
82 and 97%.
Nondiagnostic/benign FNAC and CB
Core biopsy was not representative of the lesion (B1) in 36 patients
(5%) and was benign (B2) in 17 patients (2%). Fine-needle
aspiration cytology was inadequate (C1) in 61 patients (8%) and
was benign (C2) in 74 patients (10%). When both tests were
combined, the number of cancers producing inadequate/nonre-
presentative samples in both tests (any combination of C1, C2 and
B1, B2) reduced to 19 (2.5%). These were diagnosed by a
subsequent assessment (n¼8) or open biopsy. The miss rate for
CB was 6.9%.
Table 5 summarises C1, C2, B1 and B2 results in relation to
mammographic presentation, mode of biopsy and final histology.
Table 1 Reporting categories for FNAC and for CB
Cytology reporting Core biopsy reporting
C1 Unsatisfactory B1 Unsatisfactory/normal tissue only
C2 Benign B2 Benign
C3 Atypia probably benign B3 Benign, but of uncertain malignant
potential
C4 Suspicious of malignancy B4 Suspicious of malignancy
C5 Malignant B5 Malignant
B5a Noninvasive cancer
B5b Invasive cancer
B5c Cancer of nonassessable
invasiveness
CB¼core biopsy; FNAC¼fine-needle aspiration cytology.
Table 2 Mode of FNAC and CB
CB
FNAC Stereo US Clinical Not recorded Total
Stereo 270 12 1 283
US 59 205 5 1 270
Clinical 28 96 80 4 208
Not recorded 2 2
Total 359 313 86 5 763
CB¼core biopsy; FNAC¼fine-needle aspiration cytology.
Table 3 Cytology (C) and core biopsy (B) results of 763 cases in which
malignancy was confirmed at surgical excision
B1 B2 B3 B4 B5 Total
C1 5 2 4 6 44 61
C2 5 7 14 12 36 74
C3 0 2 8 1 17 28
C4 7 3 7 18 68 103
C5 19 3 2 23 449 496
Total 36 17 35 60 614 762
a
aData on one case incomplete.
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(C2) mostly in lesions presenting as microcalcifications (12.5%
were C1 and 12.5% were C2), with stereotactic approach (13 and
15%) and with lesions proved to be DCIS (13.6 and 14%). Fine-
needle aspiration cytology was benign (C2) in 19% of ILCs.
DISCUSSION
Accurate preoperative diagnosis of carcinoma is necessary in
screen-detected lesions so that patients may be counselled
appropriately and a majority could have a single therapeutic
operation. Fine-needle aspiration cytology is a very useful test,
relatively rapid and inexpensive, less invasive owing to finer needle
size and is easier/safer in certain lesions, such as very small lesions,
lesions just under the skin or very close to the chest wall compared
with CB. In addition, FNAC maintains tactile sensitivity, allows
multidirectional passes allowing a broader sampling of the lesion
and immediate reporting where necessary. It is used extensively in
our screening centre as well as elsewhere. However, it is less
reliable at differentiating invasive cancer from DCIS, may be
limited in some cases in the assessment of tumour grade and
prognostic/predictive markers such as hormone receptors and
Her-2/neu, has a relatively high inadequate rate and is more time
consuming for pathologists. Cores can be radiographed to reveal
microcalcification to confirm accurate targeting of the lesion.
These factors have made CB now the test of choice in screen-
detected breast carcinoma in NHSBSP in the UK. Among 13290
cancers detected by the UK NHSBSP in the year 2003/2004, 93%
were diagnosed preoperatively and only 8% were diagnosed by
cytology alone, the rest by CB only or a combination of CB and
FNAC (ABS at BASO, 2005). In this study, our aim was to explore
the value of performing both FNAC and CB in the preoperative
assessment of screen-detected breast carcinoma. An initial
indeterminate FNAC result (C3 and C4) or CB result (B3 and
B4) in our institution would lead to further assessment; either
further sampling of the lesion by core biopsies, vacuum-guided
biopsies or surgery or, occasionally, with less suspicious lesions,
an early recall of patients for further mammograms and
assessment in 6–12 months time. Thus, we consider complete
sensitivity (C3 and above and B3 and above) as truly representative
of the diagnostic ability of the test, as a cancer is likely to be picked
up eventually.
The better preoperative diagnosis rate of CB in our study was
mainly owing to better diagnosis of DCIS, which mainly presented
with mammographic microcalification that often required stereo-
tactic approach. It is known that the sensitivity of FNAC is the
lowest when performed stereotactically (Britton, 1999), especially
in the assessment of microcalcifications (Pisano et al, 1998), and
our findings in this large study confirm this observation. Cores
performed for microcalcification were radiographed to confirm the
presence of calcium, which obviously improved the adequacy of
samples contributing to the improved diagnosis of DCIS by CB.
However, even with malignancy presenting as microcalcifications,
the complete sensitivity increased from 94% for CB only to 98% for
the combination of FNAC and CB.
To compare tests fairly, both FNAC and CB should be taken
from the same lesion that is later surgically excised for definitive
histology. Both tests should be performed in the same sitting,
ideally using the same guidance (clinical, US or stereotactic), and
the operator should be skilled in both techniques. Fine-needle
aspiration cytology, especially, is more operator-dependent than
CB. An adequately trained and experienced cytopathologist is
necessary to reduce the number of nondiagnostic FNACs, and the
interpretation of cytology is relatively more dependent on the
expertise of the cytopathologist than CB is on the quality of
histopathologist. Despite the large amount of literature on FNAC
and CB in breast diseases, only a few relatively small studies have
been reported, where both FNAC and CB were taken from the same
lesion in the same sitting and compared. Early studies compared
FNAC with a single ‘Tru-Cut’ needle biopsy in palpable cancers.
Results were variable and the performance of CB was often
suboptimal, with nondiagnostic biopsies in up to a third of
patients in some studies (Elston et al, 1978; Shabot et al, 1982;
Dixon et al, 1986; Cheung et al, 1987; Khanna et al, 1991). More
recent studies in palpable lesions have usually used automated CB
devices with relatively larger needle sizes and usually found CB to
be more sensitive. When both tests were performed clinically in
palpable lesions, the sensitivity of FNAC varied from 90 to 98%
and that of CB from 90 to 100%, with one study showing better
sensitivity for FNAC than CB (Ballo and Sneige, 1996; Agarwal
et al, 2003; Dennison et al, 2003). When both tests were performed
under ultrasound guidance, some found the sensitivity of the
FNAC to be equal to that of CB (Hatada et al, 2000; Westenend
et al, 2001), whereas others showed CB to be better (Chuo and
Corder, 2003). In 112 breast cancers from our symptomatic unit,
FNAC did not provide useful additional information owing to CB
Table 4 Complete sensitivity (%) of FNAC and CB with regard to histology, mammographic presentation and mode of biopsy (n¼763)
Histology Mammographic presentation Mode of Biopsy
All Cancers (invasive and DCIS) Invasive DCIS only Microcacification Soft tissue lesion Clinical US Stereo
FNAC 83 (80) 85 (84) 74 (71) 75 (73) 85 (85) 91 (95) 86 (86) 71 (72)
CB 93 (93) 93 (92) 94 (93) 94 (94) 93 (92) 95 (95) 94 (93) 95 (92)
Combined FNAC and CB 98 (97) 97 (96) 98 (98) 97 (97) 98 (97) NC (99) NC (98) NC (96)
CB¼core biopsy; DCIS¼ductal carcinoma in situ; FNAC¼fine-needle aspiration cytology; NC¼not calculable. Numbers within parentheses are those concerning 555 patients
who had both tests performed under the same guidance (clinical, US or stereotaxis).
Table 5 Percentages of inadequate (C1), nondiagnostic (B1) and benign
(C2 and B2) FNAC and CB in relation to mammographic presentation,
mode of biopsy and final histology
C1 B1 C2 B2
Mammographic presentation
Microcalcification 12.5 2.6 12.5 3.5
Soft tissue lesion 6 5.6 8.5 1.7
Mode of biopsy
Clinical 3.8 3.5 4.8 1.2
US 5.9 5.8 7.8 0.6
Stereotaxis 13.1 3.9 15.2 3.9
Final histology
Invasive ductal 5.6 5.6 5.1 1.7
Invasive lobular 7.5 3.2 19.4 0
Other invasive 7.0 3.5 12.8 4.7
DCIS 13.6 3.4 13.6 3.4
CB¼core biopsy; DCIS¼ductal carcinoma in situ; FNAC¼fine-needle aspiration
cytology.
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FNAC to improve upon the preoperative diagnosis rate (Pilgrim
and Ravichandran, 2005).
Fewer comparison studies of similar nature have been reported
with screen-detected breast cancers. In an early study of 76
cancers, stereotactic FNAC (20G, 2–3 passes) showed better
complete sensitivity and less absolute sensitivity than stereotactic
CB (20G, 2–3 passes), but all sensitivities were generally low (32–
72%) (Dowlatshahi et al, 1991). In another study of single-pass
stereotactic FNAC and CB (18G) in 65 nonpalpable breast cancers
(Lifrange et al, 1997), FNAC was inadequate in 22% and benign in
34%. The corresponding figures for CB were 3 and 38%. It is now
known that a minimum of five, often more, cores are necessary,
especially with microcalcification, to reduce the number of
inadequate specimens and false-negatives (Liberman et al, 1994;
Romanelli and Smith, 1999; Michell, 2000). In a study of 81
carcinomas presenting as microcalcification, complete sensitivity
of stereotactic FNAC (up to three passes) was 65% compared with
97.5% for stereotactic CB (14G, 5–10 passes) (Newman et al,
2001). There is a risk that when FNAC is performed as an adjunct
to CB, it may be relegated to a second place and is not as
satisfactorily performed or evaluated as it would have been if it
were the only diagnostic test performed, resulting in poor
sensitivity and specificity with high inadequate rates (Ibrahim
et al, 2001). It has been reported that introducing CB in a screening
unit that was previously running a very successful FNAC-based
service may result in a reduction in the performance of FNAC
(Newman et al, 2001). Relatively more FNACs were performed
clinically without image guidance in our study compared with CB.
This was in part owing to FNAC being used to assess whether the
lesion was truly palpable in a situation where a radiologically
visible cancer is associated with a vaguely palpable mass at the
site. For example, a lesion visible on ultrasonography with a
corresponding vaguely palpable abnormality may be sampled by
CB under US guidance and by FNAC under clinical guidance. If
both confirm malignancy, it may be inferred that the radiological
and palpable lesions are the same. However, more FNAC being
performed clinically did not appear to have affected the
performance of FNAC adversely in our study, as the sensitivity
of FNAC was the highest when performed clinically and the
inadequate rate lowest. These results, however, probably reflect
more of the nature and size of the lesion being sampled rather than
the mode of sampling.
Our study confirms an advantage of combining FNAC and CB
for screening-detected breast cancers. The complete sensitivity
increases from 93% for CB only to 98% when both tests are
combined. The increase is similar for both invasive cancers and
DCIS. This additional benefit by FNAC is probably owing to its
ability to sample a larger area by multidirectional passes of the
needle and the maintenance of tactile sensitivity. Adding FNAC to
CB results in only minimal additional trauma to the patient, so the
combined approach is unlikely to result in extra complications and
it would help to maintain the breast cytology expertise locally.
However, whether this modest increase in diagnostic sensitivity by
additional FNAC is cost effective is difficult to comment, as we
have not performed a formal cost-effective analysis. Fine-needle
aspiration cytology is inexpensive in terms of disposables (of the
order of d1–2, 1.46–2.92h), but it is time consuming for
pathologists and this is probably where the real ‘cost’ of FNAC
lies. Core biopsy costs approximately d20 (29h) per biopsy in
disposables alone. We hoped that it might be possible to identify a
subgroup of lesions, which would benefit most from having both
tests performed but did not find one. It would, however, be
reasonable to undertake CB only in lesions that are clinically or
radiologically suspicious/malignant, as these lesions would not be
overlooked if the CB were negative.
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